title: Noninvasive and curative radiation therapy for sebaceous carcinoma of the eyelid.
abstract: OBJECTIVE
  Sebaceous carcinoma of the eyelid is a rare malignancy. Surgical excision remains the standard and most reliable curative treatment. However, surgery is sometimes not possible because many patients are elderly, and it frequently causes functional and cosmetic impairment of the eyelid. We therefore carried out a study to determine the role of radiation therapy in relation to sebaceous carcinoma of the eyelid.
  
  
  METHODS
  Thirteen patients with sebaceous carcinoma of the eyelid underwent radiation therapy with curative intent. There were 6 men and 7 women, and their ages at irradiation ranged from 60 to 85 years (median, 78 years). Only 1 patient had cervical lymph node metastasis, and none of the patients had distant metastasis. A total dose of 50 to 66.6 Gy (median, 60 Gy) was delivered to tumor sites in 22 to 37 fractions.
  
  
  RESULTS
  All irradiated tumors were controlled at a median follow-up period of 55 months. Only 1 patient had recurrence of cervical lymph node metastasis outside the radiation field, at 22 months after irradiation. The 5-year local progression-free and disease-free rates were 100% and 89%, respectively. The overall and disease-free survival rates at 5 years were 100% and 89%, respectively. Although acute and transient therapy-related reactions of Grade 2 or less were observed, there were no severe toxicities of Grade 3 or greater.
  
  
  CONCLUSIONS
  Radiation therapy is a safe and effective treatment for patients with sebaceous carcinoma of the eyelid. It appears to contribute to prolonged survival as a result of good tumor control, and it also facilitates functional and cosmetic preservation of the eyelid.
authors.affiliation: Department of Radiology, Yokohama City University Graduate School of Medicine, Yokohama, Kanagawa, Japan. mhata@syd.odn.ne.jp
authors.forename: Masaharu
authors.initials: M
authors.lastname: Hata
authors.forename: Izumi
authors.initials: I
authors.lastname: Koike
authors.forename: Motoko
authors.initials: M
authors.lastname: Omura
authors.forename: Jiro
authors.initials: J
authors.lastname: Maegawa
authors.forename: Ichiro
authors.initials: I
authors.lastname: Ogino
authors.forename: Tomio
authors.initials: T
authors.lastname: Inoue
mesh_terms: D018266:Adenocarcinoma, Sebaceous / Q000473:pathology / Q000532:radiotherapy* / Q000556:secondary / Q000601:surgery; D000368:Aged; D000369:Aged, 80 and over; D018572:Disease-Free Survival; D005142:Eyelid Neoplasms / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D010781:Photography; D011879:Radiotherapy Dosage; D035583:Rare Diseases / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery; D012626:Sebaceous Gland Neoplasms / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery